- Home
- SAIH vs ERNA Comparison
SAIH vs ERNA Comparison
Compare SAIH & ERNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAIH
- ERNA
- Stock Information
- Founded
- SAIH 2019
- ERNA 2018
- Country
- SAIH Singapore
- ERNA United States
- Employees
- SAIH N/A
- ERNA N/A
- Industry
- SAIH
- ERNA Biotechnology: Pharmaceutical Preparations
- Sector
- SAIH
- ERNA Health Care
- Exchange
- SAIH NYSE
- ERNA Nasdaq
- Market Cap
- SAIH 13.4M
- ERNA 14.2M
- IPO Year
- SAIH N/A
- ERNA N/A
- Fundamental
- Price
- SAIH $6.98
- ERNA $0.18
- Analyst Decision
- SAIH
- ERNA
- Analyst Count
- SAIH 0
- ERNA 0
- Target Price
- SAIH N/A
- ERNA N/A
- AVG Volume (30 Days)
- SAIH 44.2K
- ERNA 465.0K
- Earning Date
- SAIH 04-28-2025
- ERNA 06-13-2025
- Dividend Yield
- SAIH N/A
- ERNA N/A
- EPS Growth
- SAIH N/A
- ERNA N/A
- EPS
- SAIH N/A
- ERNA N/A
- Revenue
- SAIH $5,543,000.00
- ERNA $535,000.00
- Revenue This Year
- SAIH N/A
- ERNA N/A
- Revenue Next Year
- SAIH N/A
- ERNA N/A
- P/E Ratio
- SAIH N/A
- ERNA N/A
- Revenue Growth
- SAIH N/A
- ERNA 365.22
- 52 Week Low
- SAIH $3.00
- ERNA $0.15
- 52 Week High
- SAIH $26.98
- ERNA $2.63
- Technical
- Relative Strength Index (RSI)
- SAIH N/A
- ERNA 35.42
- Support Level
- SAIH N/A
- ERNA $0.17
- Resistance Level
- SAIH N/A
- ERNA $0.25
- Average True Range (ATR)
- SAIH 0.00
- ERNA 0.02
- MACD
- SAIH 0.00
- ERNA -0.01
- Stochastic Oscillator
- SAIH 0.00
- ERNA 22.22
About SAIH SAIHEAT LIMITED
Saiheat Ltd develops technologies for the Computing Center Ecosystem (ACCE), a next-gen computing center featuring high-performance servers, liquid cooling, and systems for capturing and recycling computing heat. It aims to reduce the carbon footprint of Bitcoin mining and AI operations. The Company has four reportable segments: equipment sales, hosting, mining pool business, and mining.
About ERNA Eterna Therapeutics Inc.
Ernexa Therapeutics Inc is a biotechnology company. The company develops transformational new medicines using various cell engineering technologies for cancer and autoimmune diseases. The proprietary technology of the company transforms induced pluripotent stem cells (iPSCs) into induced mesenchymal stem cells (iMSCs), offering potential off-the-shelf treatment solutions without the need for patient-specific cell harvesting.